DNTH SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Dianthus Therapeutics Reports Q3 2026 Financial Results and Highlights Recent Business Achievements

Nov 4, 2026

8-K

Dianthus Therapeutics Reports Q2 2026 Financial Results and Business Progress

Aug 4, 2026

8-K

Dianthus Therapeutics Advances Autoimmune Pipeline with Claseprubart and DNTH212

Jun 12, 2026

8-K

Dianthus Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 22, 2026

8-K

Dianthus Therapeutics Reports Q1 2026 Financial Results and Business Updates

May 5, 2026

8-K

Dianthus Therapeutics Advances Autoimmune Pipeline with Claseprubart and DNTH212

Mar 26, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

FIXED PRICE OFFERING | Offering amount: $624,999,648 | Shares: 7,716,050 | Price: $81.000 | Bank: Jefferies

Mar 11, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $400,000,000 | Bank: Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities, William Blair

Mar 9, 2026

424B5

REGISTERED OFFERING

Sep 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies, TD Cowen, Evercore ISI, Stifel

Sep 8, 2025

424B5

ATM | Offering amount: $200,000,000

Oct 11, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 23,655,372

Oct 11, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

September 2026 SHELF + ATM

Sep 18, 2026

S-3MEF

Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]

Mar 10, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 9, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jan 28, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2025

Form RW - Registration Withdrawal Request

Oct 21, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 11, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 11, 2024

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

SCHEDULE 13G

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Oct 30, 2026

CARR EDWARD (Reporting)

Sep 18, 2026

144

Form 144 - Report of proposed sale of securities

Sep 17, 2026

Randhawa Simrat (Reporting)

Sep 3, 2026

144

Form 144 - Report of proposed sale of securities

Sep 1, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 2, 2026

CORRESP

Form CORRESP - Correspondence

Jan 29, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 29, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 10, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 10, 2024

CORRESP

Form CORRESP - Correspondence

Oct 7, 2024

Dianthus Therapeutics, Inc. DNTH · SEC Filings